Cancer Venous Thromboembolism (VTE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1046 participants.

Also called NCT02073682

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,046 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02073682
  • EudraCT 2014-004708-30
Other papers using this trial's data
  • Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism The New England journal of medicine, 2018-02-15 DOI, PubMed 29231094
  • Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer Haematologica, 2024-06-01 DOI, PubMed 37855029, PMC11141682 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, France, Hungary, Italy, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02073682. Randomized; no masking; primary purpose treatment. Start 2015-07-16 (actual); primary completion 2017-09-15 (actual). Results posted on 2018-10-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cancer Venous Thromboembolism (VTE)
Condition
Venous Thromboembolism (VTE)
Condition
Pulmonary Embolism (PE)
Condition
Cancer
Intervention (Drug)
Edoxaban
Intervention (Drug)
Dalteparin
Intervention (Drug)
Low molecular weight heparin
Lead sponsor
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct02073682
Content hash
19fce2a88bba781e92f8bbca3b3b5a342a3c44ebede83201be328fd31202c903